Literature DB >> 25065544

Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control.

S Bhattacharyya1, C Iyegbe2, Z Atakan1, R Martin-Santos3, J A Crippa4, X Xu2, S Williams5, M Brammer5, K Rubia6, D Prata1, D A Collier2, P K McGuire1.   

Abstract

BACKGROUND: What determines inter-individual variability to impairments in behavioural control that may underlie road-traffic accidents, and impulsive and violent behaviours occurring under the influence of cannabis, the most widely used illicit drug worldwide?
METHOD: Employing a double-blind, repeated-measures design, we investigated the genetic and neural basis of variable sensitivity to cannabis-induced behavioural dyscontrol in healthy occasional cannabis users. Acute oral challenge with placebo or Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, was combined with functional magnetic resonance imaging, while participants performed a response inhibition task that involved inhibiting a pre-potent motor response. They were genotyped for rs1130233 single nucleotide polymorphisms (SNPs) of the protein kinase B (AKT1) gene.
RESULTS: Errors of inhibition were significantly (p = 0.008) increased following administration of THC in carriers of the A allele, but not in G allele homozygotes of the AKT1 rs1130233 SNP. The A allele carriers also displayed attenuation of left inferior frontal response with THC evident in the sample as a whole, while there was a modest enhancement of inferior frontal activation in the G homozygotes. There was a direct relationship (r = -0.327, p = 0.045) between the behavioural effect of THC and its physiological effect in the inferior frontal gyrus, where AKT1 genotype modulated the effect of THC.
CONCLUSIONS: These results require independent replication and show that differing vulnerability to acute psychomotor impairments induced by cannabis depends on variation in a gene that influences dopamine function, and is mediated through modulation of the effect of cannabis on the inferior frontal cortex, that is rich in dopaminergic innervation and critical for psychomotor control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25065544     DOI: 10.1017/S0033291714000920

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  12 in total

1.  GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.

Authors:  Rajiv Radhakrishnan; Patrick D Skosnik; Jose Cortes-Briones; R Andrew Sewell; Michelle Carbuto; Ashley Schnakenberg; John Cahill; Fred Bois; Handan Gunduz-Bruce; Brian Pittman; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Neuropsychopharmacology       Date:  2015-03-02       Impact factor: 7.853

2.  Cannabis and Depression.

Authors:  Daniel Feingold; Aviv Weinstein
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Network analysis of the genomic basis of the placebo effect.

Authors:  Rui-Sheng Wang; Kathryn T Hall; Franco Giulianini; Dani Passow; Ted J Kaptchuk; Joseph Loscalzo
Journal:  JCI Insight       Date:  2017-06-02

4.  Impact of At Least 2 Years of Synthetic Cannabinoid Use on Cognitive and Psychomotor Functions Among Treatment-Seeking Male Outpatients.

Authors:  Gokhan Umut; Cuneyt Evren; Murat Ilhan Atagun; Ozge Hisim; Hanife Yilmaz Cengel; Muge Bozkurt; Cahit Keskinkilic
Journal:  Cannabis Cannabinoid Res       Date:  2020-06-05

5.  Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects.

Authors:  André Schmidt; Felix Müller; Patrick C Dolder; Yasmin Schmid; Davide Zanchi; Matthias E Liechti; Stefan Borgwardt
Journal:  Int J Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 5.176

Review 6.  Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.

Authors:  Marco Colizzi; Sagnik Bhattacharyya
Journal:  Curr Addict Rep       Date:  2017-04-29

Review 7.  Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.

Authors:  Marco Colizzi; Mirella Ruggeri; Sagnik Bhattacharyya
Journal:  Front Psychol       Date:  2020-05-14

Review 8.  A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis.

Authors:  Lani Cupo; Eric Plitman; Elisa Guma; M Mallar Chakravarty
Journal:  Transl Psychiatry       Date:  2021-04-13       Impact factor: 6.222

Review 9.  Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence.

Authors:  Grace Blest-Hopley; Marco Colizzi; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  Front Psychiatry       Date:  2020-08-26       Impact factor: 4.157

Review 10.  The neuropsychopharmacology of cannabis: A review of human imaging studies.

Authors:  Michael A P Bloomfield; Chandni Hindocha; Sebastian F Green; Matthew B Wall; Rachel Lees; Katherine Petrilli; Harry Costello; M Olabisi Ogunbiyi; Matthijs G Bossong; Tom P Freeman
Journal:  Pharmacol Ther       Date:  2018-10-19       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.